EMA Recommends Approval of New Biosimilars and Innovative Therapies

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently made significant strides in advancing patient access to innovative therapies. During its December 9-12, 2024, meeting, the CHMP recommended approval for six new biosimilars, offering more affordable alternatives to existing biologic medications.

Beyond biosimilars, the CHMP also greenlighted two novel therapies. Biocon’s YESTINTEK (ustekinumab) received approval for treating adults and children with plaque psoriasis, as well as adults with psoriatic arthritis or Crohn’s disease. CuraTeq Biologic’s ZEFYLTI (filgrastim) was approved for the treatment of neutropenia and the mobilization of peripheral blood progenitor cells.

These approvals mark a crucial step towards expanding treatment options for patients across various conditions. Biosimilars offer a valuable opportunity to increase access to essential medicines, while the novel therapies like YESTINTEK and ZEFYLTI represent advancements in treating complex diseases.

[View source.]

Stay informed about the latest developments in the pharmaceutical landscape. Subscribe to our newsletter for regular updates on drug approvals, clinical trials, and industry news.